C2 and cancer: In 21 cancer types, 36.51% of cancers had significantly better OS predicted by the 87 scSTAR-C2 marker genes upregulated after ATHENA treatment, while only 18.61% of cancers had significantly better OS predicted by the 100 scSTAR-C1 marker genes downregulated after ATHENA treatment.